Experimental and emerging therapies for chronic hepatitis C virus infection

Bibliography

• GLOBAL SURVEILLANCE AND CONTROL OF HEPATITIS C: Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. Viral. Hepat. (1999) 6(1):35–47.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health Consensus Development Conference Panel statement: management of hepatits C. Hepatology (1997) 26\(Suppl. 1):25–105.
   Google Scholar
• ZEIN NN, RAKELA J, KRAWITT EL, REDDY KR, TOMINAGA T, PERSING DH: Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann. Intern. Med. (1996) 125(8):634–639.
   PubMed Web of Science ®Google Scholar
• SIMMONDS P, ALBERTI A, ALTER HJ et al.: A proposed system for the nomenclature of hepatitis C viral genotypes (letter). Hepatology (1994) 19(5):1321–1324.
   PubMed Web of Science ®Google Scholar
• ZEIN NN: Clinical significance of hepatitis C virus genotypes. Clin. ll/licrobiol. Rev (2000) 13(2):223–235.
   PubMed Web of Science ®Google Scholar
• ISAACS A, LINDENMANN J: Virus interference. I. The interferon. Proc. R. Soc. Loud. B. Biol. Sci. (1957) 147(927):258–267.
   PubMed Web of Science ®Google Scholar
• DIANZANI F: Biological basis for the clinical use of interferon. Gut (1993) 34(2 Suppl):574–576.
   Google Scholar
• ROTHSTEIN KD, MUNOZ SJ: Interferon and other therapies for hepatitis B and hepatitis C infections. Clin. Lab. Med. (1996) 16(2):465–491.
   PubMed Web of Science ®Google Scholar
• JONAS MM: Interferon-alpha for viral hepatitis. j Pediatr. Gastroenterol. Num (1996) 23(2):93–106.
   PubMed Web of Science ®Google Scholar
• LENGYEL P: Biochemistry of interferons and their actions. Ann. Rev Bloch= (1982) 51:251–282.
   PubMed Web of Science ®Google Scholar
• HORISBERGER MA, STAEHELI P, HALLER 0: Interferon induces a unique protein in mouse cells bearing a gene for resistance to influenza virus. Proc. Natl. Acad. Sci. USA (1983) 80(7):1910–1914.
   PubMed Web of Science ®Google Scholar
• HERON I, HOKLAND M, BERG K: Enhanced expression of beta2-microglobulin and HLA antigens on human lymphoid cells by interferon. Proc. Nati Acad. Sci. USA (1978) 75(12):6215–6219.
   PubMed Web of Science ®Google Scholar
• TILG H: New insights into the mechanismsof interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology (1997) 112(3):1017–1021.
   PubMed Web of Science ®Google Scholar
• GARCIA-MONZON C, GARCIA-BUEY L, GARCIA-SANCHEZ A, PAJARES JM, MORENO-OTERO R: Down-regulation of intercellular adhesion molecule 1 on hepatocytes in viral chronic hepatitis treated with interferon alfa-2b. Gastroenterology (1993) 105(2):462–469.
   PubMed Web of Science ®Google Scholar
• THOMSON BJ, DORAN M, LEVER AM, WEBSTER AD: Alpha-interferon therapy for non-A, non-B hepatitis transmitted by gammaglobulin replacement therapy. Lancet (1987) 1(8532):539–541.
   PubMed Web of Science ®Google Scholar
• LOCKNER D, BRATT G, LINDBORG A, TORNEBOHM E: Acute unidentified hepatitis in a hypogammaglobulinaemic patient on intravenous gammaglobulin successfully treated with interferon. Acta Med. Scand (1987) 221(4):413–415.
   PubMed Web of Science ®Google Scholar
• HOOFNAGLE JH, MULLEN KD, JONES DB et al.: Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N. Engl. J Med. (1986) 315(25):1575–1578.
   PubMed Web of Science ®Google Scholar
• WEILAND 0, SCHVARCZ R, WEJSTAL R, NORKRANS G, FOBERG U, FRYDEN A: Interferon alpha-2b treatment of chronic posttransfusion non-A, non-B hepatitis: interim results of a randomized controlled open study. Scand. J Infect. Dis. (1989) 21(2):127–132.
   PubMed Web of Science ®Google Scholar
• LEE CA, KERNOFF PB, KARAYIANNIS P, THOMAS HC: Interferon therapy for chronic non-A non-B and chronic delta liver disease in haemophilia. BE j Haematol. (1989) 72(2):235–238.
   PubMed Web of Science ®Google Scholar
• KIYOSAWA K, SODEYAMA T, NAKANO Y et al.: Treatment of chronic non-A non-B hepatitis with human interferon beta: a preliminary study. Antiviral Res. (1989) 12(3):151–161.
   PubMed Web of Science ®Google Scholar
• KAKUMU S, ARAO M, YOSHIOKA K et al.: Pilot study of recombinant human alpha-interferon for chronic non-A, non-B hepatitis. Am. j Gastroenterol. (1989) 84(1):40–45.
   PubMed Web of Science ®Google Scholar
• DI BISCEGLIE AM, MARTIN P, KASSIANIDES C etal.: Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo- controlled trial. N Engl. j Med. (1989) 321(22):1506–1510.
   Google Scholar
• DAVIS GL, BALART LA, SCHIFF ER et al.: Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl. Med. (1989) 321(22):1501–1506.
   PubMed Web of Science ®Google Scholar
• SCHVARCZ R, WEILAND 0, WEJSTAL R, NORKRANS G, FRYDEN A, FOBERG U: A randomized controlled open study of interferon alpha-2b treatment of chronic non-A, non-B posttransfusion hepatitis: no correlation of outcome to presence of hepatitis C virus antibodies. Scand. j Infect. Dis. (1989) 21(6):617–625.
   PubMed Web of Science ®Google Scholar
• MARCELLIN P, BOYER N, GIOSTRA E et al.: Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology (1991) 13(3):393–397.
   PubMed Web of Science ®Google Scholar
• SAEZ-ROYUELA F, PORRES JC, MORENO A et al.: High doses of recombinant alpha-interferon or gamma-interferon for chronic hepatitis C: a randomized, controlled trial. Hepatology (1991) 13(2):327–331.
   PubMed Web of Science ®Google Scholar
• SARACCO G, ROSINA F, TORRANI CERENZIA MR et al.: A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis.
   Google Scholar
• ▪Hepatol. (1990) 11\(Suppl. 1):S43–S49.
   Google Scholar
• NAKANO Y, KIYOSAWA K, SODEYAMA T, TANAKA E: Comparative study of clinical, histological, and immunological responses to interferon therapy in type non-A, non-B, and type B chronic hepatitis. Am.
   Google Scholar
• ▪Gastroenterol. (1990) 85(1):24–29.
   Google Scholar
• OKUNO T, SHINDO M, ARAI K, MATSUMOTO M, TAKEDA M: Histological improvement of chronic hepatitis B, and non-A, non-B with interferon treatment: application of a numerical scoring system for evaluating sequential morphologic changes. Gastroenterol. fpri. (1990) 25(1):70–77.
   Google Scholar
• KAKUMU S, ARAO M, YOSHIOKA K et al.: Recombinant human alpha-interferon therapy for chronic non-A, non-B hepatitis: second report. Am. j Gastroenterol. (1990) 85(6):655–659.
   PubMed Web of Science ®Google Scholar
• CARITHERS RL JR, EMERSON SS: Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology (1997) 26(3 Suppl. 1):83S–88S.
   Google Scholar
• ZEIN NN, RAKELA J: Interferon therapy in hepatitis C. Semirr. Gastrointest. Dis. (1995) 6(1):46–53.
   PubMedGoogle Scholar
• ZEIN NN: Interferons in the management of viral hepatitis. Cytokirres Cell Mol. Ther (1998) 4(4):229–241.
   PubMedGoogle Scholar
• PATTERSON JL, FERNANDEZ-LARSSON R: Molecular mechanisms of action of ribavirin. Rev Infect. Dis. (1990) 12(6):1139–1146.
   PubMedGoogle Scholar
• NING Q, BROWN D, PARODO J et al: Ribavirin inhibits viral induced macrophage production of tumor necrosis factor, interleukin 1 and procoagulant activity and preserves Thl cytokine production, but inhibits Th2 cytokine response (abstract). Hepatology (1996) 26(4 Suppl):355A.
   Google Scholar
• DUSHEIKO G, MAIN J, THOMAS H et al.: Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. I Hepatol (1996) 25(5):591–598.
   Web of Science ®Google Scholar
• DI BISCEGLIE AM, BACON BR, KLEINER DE, HOOFNAGLE JH: Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. I Hepatol (1994) 21(6):1109–1112.
   Web of Science ®Google Scholar
• POYNARD T, MARCELLIN P, LEE SS et al.: Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHITL Lancet (1998) 352(9138):1426–1432.
   Google Scholar
• CHEMELLO L, CAVALLETTO L, BERNARDINELLO E, GUIDO M, PONTISSO P, ALBERTI A: The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. j Hepatol (1995) 23\(Suppl. 2):8–12.
   Google Scholar
• MCHUTCHISON JG, GORDON SC, SCHIFF ER et al: Interferon alfa-2b alone or in combination with ribavirin as intial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl. Med. (1998) 339(20:1485–1492.
   Google Scholar
• DAVIS GL, ESTEBAN-MUR R, RUSTGI V et al: Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl. j Med. (1998) 339(21):1493–1499.
   Google Scholar
• BACON BR: Available options for treatment of interferon nonresponders. Am. Med. (1999) 107(6B):675–705.
   Google Scholar
• SCHALM SW, HANSEN BE, CHEMELLO L etal.: Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. j Hepatol (1997) 26(5):961–966.
   Google Scholar
• KIM WR, POTERUCHA JJ, HERMANS JE et al.: Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann. Intern. Med. (1997) 127(10):866–874.
   PubMed Web of Science ®Google Scholar
• WONG JB, POYNARD T, LING MH, ALBRECHT JK, PAUKER SG: Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. Am. I Gastroenterol (2000) 95(6):1524–1530.
   PubMed Web of Science ®Google Scholar
• VAN THIEL DH, FRIEDLANDER L, MOLLOY PJ et al.: Retreatment of hepatitis C interferon non-responders with larger doses of interferon with and without phlebotomy. Hepatogastroenterology (1996) 43(12):1557–1561.
   PubMed Web of Science ®Google Scholar
• LINDSAY KL, DAVIS GL, SCHIFF ER et al.: Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group. Hepatology (1996) 24(5):1034–1040.
   PubMed Web of Science ®Google Scholar
• LAYDEN TJ: Principles of interferon induction therapy. Am. j Med. (1999) 107(6B):715–735.
   Google Scholar
• HEATHCOTE EJ, KEEFFE EB, LEE SS et al.: Re-treatment of chronic hepatitis C with consensus interferon. Hepatology (1998) 27(4):1136–1143.
   PubMed Web of Science ®Google Scholar
• ABDELMALEK MF, HARRISON ME, GROSS JB JR et al: Treatment of chronic hepatitis C with interferon with or without ursodeoxycholic acid: a randomized prospective trial. ..J. Clin. Gastroenterol (1998) 26(2):130–134.
   PubMed Web of Science ®Google Scholar
• BRILLANTI S, LEVANTESI F, MASI L, FOLI M, BOLONDI L: Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. Hepatology (2000) 32(3):630–634.
   PubMed Web of Science ®Google Scholar
• DI BISCEGLIE AM, BONKOVSKY HL, CHOPRA S et al.: Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology (2000) 32(1):135–138.
   PubMed Web of Science ®Google Scholar
• PATRICK L: Hepatitis C: epidemiology and review of complementary/alternative medicine treatments. Altern. Med. Rev (1999) 4(4):220–238.
   PubMedGoogle Scholar
• NICHOLSON KG, WISELKA MJ: Amantadine for influenza A. BMJ(1991) 302(6774):425–426.
   PubMed Web of Science ®Google Scholar
• OLYNYK JK, REDDY KR, DI BISCEGLIE AM et al: Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology (1995) 108(4):1104–1109.
   PubMed Web of Science ®Google Scholar
• LAM NE NEUMANN AU, GRETCH DR, WILEY TE, PERELSON AS, LAYDEN TJ: Dose-dependent acute clearance of hepatitis C geno type 1 virus with interferon alfa. Hepatology (1997) 26(1):226–231.
   PubMed Web of Science ®Google Scholar
• NEUMANN AU, LAM NE DAHARI H et al.: Hepatitis C viral dynamics in viva and the antiviral efficacy of interferon-alpha therapy. Science (1998) 282(5386):103–107.
   Google Scholar
• ZEUZEM S, FEINMAN SV, RASENACK J et al: Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl. I Med. (2000) 343(23):1666–1672.
   PubMed Web of Science ®Google Scholar
• HEATHCOTE EJ, SHIFFMAN ML, COOKSLEY WG et al: Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl. I Med. (2000) 343(23):1673–1680.
   PubMed Web of Science ®Google Scholar
• FRIED MW, SHIFFMAN ML, REDDY RK et al.: Pegylated (40 kDa) interferon alfa-2a (PEGASYS) in combination with ribavirin: efficacy and safety results from a Phase III, randomized, actively-controlled, multicenter study (abstract). Gastroenterology (2001) 120(5 Suppl. 1):A–55.
   Google Scholar
• GAGLIO PJ, REGENSTEIN FG, VLACOS MN, BARTHOLOMEW D, RANDAZZO P: Pegylated interferon and ribavirin for the treatment of HCV infected patients who failed previous interferon therapy (abstract). Gastroenterology (2001) 120(5 Suppl. 1):A–384.
   Google Scholar
• LOHMANN V, KOCH JO, BARTENSCHLAGER R: Processing pathways of the hepatitis C virus proteins. Hepatol (1996) 24(2 Suppl):11–19.
   Google Scholar
• TOMEI L, FAILLA C, SANTOLINI E, DE FRANCESCO R, LA MONICA N: N53 is a serine protease required for processing of hepatitis C virus polyprotein. Viral. (1993) 67(7):4017–4026.
   PubMed Web of Science ®Google Scholar
• MANABE S, FUKE I, TANISHITA 0 et al.: Production of nonstructural proteins of hepatitis C virus requires a putative viral protease encoded by N53. Virology (1994) 198(2):636–644.
   Google Scholar
• D'SOUZA ED, O'SULLIVAN E, AMPHLETT EM, ROWLANDS DJ, SANGAR DV, CLARKE BE: Analysis of NS3-mediated processing of the hepatitis C virus non-structural region in vitro. I Gen. Viral. (1994) 75(Pt 12):3469–3476.
   PubMedGoogle Scholar
• PIERONI L, SANTOLINI E, FIPALDINI C, PACINI L, MIGLIACCIO G, LA MONICA N: In vitro study of the NS2-3 protease of hepatitis C virus. j Viral. (1997) 71(9):6373–6380.
   PubMed Web of Science ®Google Scholar
• DE FRANCESCO R, NEDDERMANN P, TOMEI L, STEINKUHLER C, GALLINARI P, FOLGORI A: Biochemical and immunologic properties of the nonstructural proteins of the hepatitis C virus: implications for development of antiviral agents and vaccines. Sea-dm Liver Dis. (2000) 20(1):69–83.
   PubMed Web of Science ®Google Scholar
• FAILLA C, TOMEI L, DE FRANCESCO R: An amino-terminal domain of the hepatitis C virus N53 protease is essential for interaction with NS4A. j Viral. (1995) 69(3):1769–1777.
   PubMed Web of Science ®Google Scholar
• PIZZI E, TRAMONTANO A, TOMEI L et al.: Molecular model of the specificity pocket of the hepatitis C virus protease: implications for substrate recognition. Proc. Natl. Acad. Li. USA (1994) 91(3):888–892.
   PubMed Web of Science ®Google Scholar
• URBANI A, BIANCHI E, NARJES F et al.: Substrate specificity of the hepatitis C virus serine protease NS3. j Biol. Chem. (1997) 272(14):9204–9209.
   PubMed Web of Science ®Google Scholar
• ZHANG R, DURKIN J, WINDSOR WT, MCNEMAR C, RAMANATHAN L, LE HV: Probing the substrate specificity of hepatitis C virus NS3 serine protease by using synthetic peptides. I ViraL (1997) 71(8):6208–6213.
   PubMed Web of Science ®Google Scholar
• AL RH, XIE Y, WANG Y, HAGEDORN CH: Expression of recombinant hepatitis C virus non-structural protein 5B in Escherichia colt. Virus Res. (1998) 53(2):141–149.
   PubMed Web of Science ®Google Scholar
• BEHRENS SE, TOMEI L, DE FRANCESCO R: Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. Embo. (1996) 15(1):12–22.
   PubMed Web of Science ®Google Scholar
• LOHMANN V, KORNER E HERIAN U, BARTENSCHLAGER R: Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. I Viral. (1997) 71(11):8416–8428.
   PubMed Web of Science ®Google Scholar
• LESBURG CA, CABLE MB, FERRARI E, HONG Z, MANNARINO AF, WEBER PC: Crystal structure of the RNA- dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat. Struct. Biol. (1999) 6(10):937–943.
   PubMedGoogle Scholar
• AGO H, ADACHI T, YOSHIDA A etal.:Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure Fold. Des. (1999) 7(11):1417–1426.
   Google Scholar
• HONG Z, STANDRING DN, BAROUDY B, LAU JY: Development of novel anti-HCV therapies: HCV protease, helicase, and polymerase as therapeutic targets. Acta GastroenteraL Belg. (2000) 63(2):210–212.
   PubMed Web of Science ®Google Scholar
• FERRARI E, WRIGHT-MINOGUE J, FANG JW, BAROUDY BM, LAU JY, HONG Z: Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coli Viral. (1999) 73(2):1649–1654.
   Google Scholar
• LOHMANN V, ROOS A, KORNER F, KOCH JO, BARTENSCHLAGER R: Biochemical and kinetic analyses of NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Virology (1998) 249(1):108–118.
   PubMed Web of Science ®Google Scholar
• TSUKIYAMA-KOHARA K, IIZUKA N, KOHARA M, NOMOTO A: Internal ribosome entry site within hepatitis C virus RNA. J. Viral. (1992) 66(3):1476–1483.
   PubMed Web of Science ®Google Scholar
• LEMON M: Therapy and clinical trials. Cum: Opin. LipidaL (1997) 8(1):U13–U14.
   PubMedGoogle Scholar
• CECH TR: The chemistry of self-splicing RNA and RNA enzymes. Science (1987) 236(4808):1532–1539.
   PubMed Web of Science ®Google Scholar
• UHLENBECK OC: A small catalytic oligoribonucleotide. Nature (1987) 328(6131):596–600.
   PubMed Web of Science ®Google Scholar
• BARTOLOME J, MADEJON A, CARRENO V: Ribozymes: structure, characteristics and use as potential antiviral agents. I HepataL (1995) 22(1 Suppl):57–64.
   PubMedGoogle Scholar
• ZU PUTLITZ J, ENCKE J, WANDS JR:The use of antisense and other molecular approaches to therapy of chronic viral hepatitis. Viral Hepatitis Reviews (1998) 4:207–227.
   Google Scholar
• LIEBER A, HE CY, POLYAK SJ, GRETCH DR, BARR D, KAY MA: Elimination of hepatitis C virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes. I ViraL (1996) 70(12):8782–8791.
   PubMed Web of Science ®Google Scholar
• LEE PA, BLATT LM, BLANCHARD KS etal.: Pharmacokinetics and tissue distribution of a ribozyme directed against hepatitis C virus RNA following subcutaneous or intravenous administration in mice. Hepatology (2000) 32(3) :640–646.
   Google Scholar
• WELCH PJ, TRITZ R, YEI S, LEAVITT M, YU M, BARBER J: A potential therapeutic application of hairpin ribozymes: in vitro and in vivo studies of gene therapy for hepatitis C virus infection. Gene Ther. (1996) 3(10:994–1001.
   PubMedGoogle Scholar
• GURA T: Antisense has growing pains. Science (1995) 270(5236):575–577.
   PubMed Web of Science ®Google Scholar
• BRANCH AD: A hitchhiker's guide to antisense and nonantisense biochemical pathways. Hepatology (1996) 24(6):1517–1529.
   PubMed Web of Science ®Google Scholar
• BRANCH AD: A good antisense molecule is hard to find. Trends Biochem. Sri. (1998) 23(2):45–50.
   PubMed Web of Science ®Google Scholar
• WHITTON JL: Antisense treatment of viral infection. Adv. Virus Res. (1994) 44:267–303.
   PubMed Web of Science ®Google Scholar
• SHINDO M, DI BISCEGLIE AM, BIS WAS R, MIHALIK K, FEINSTONE SM: Hepatitis C virus replication during acute infection in the chimpanzee. j Infect. Dis. (1992) 166(2):424–427.
   PubMed Web of Science ®Google Scholar
• AGNELLO V, ABEL G, KNIGHT GB, MUCHMORE E: Detection of widespread hepatocyte infection in chronic hepatitis C. Hepatology (1998) 28(2)573–584.
   Google Scholar
• CHIEN DY, CHOO QL, TABRIZI A et al.: Diagnosis of hepatitis C virus (HCV) infection using an immunodominant chimeric polyprotein to capture circulating antibodies: reevaluation of the role of HCV in liver disease. Proc. Nati Acad. Li. USA (1992) 89(20:10011–10015.
   PubMedGoogle Scholar
• WEINER AJ, GEYSEN HM, CHRISTOPHERSON C et al.: Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc. Nati Acad. Sci. USA (1992) 89(8):3468–3472.
   PubMed Web of Science ®Google Scholar
• SHIMIZU YK, IGARASHI H, KIYOHARA T etal.: A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. Virology (1996) 223(2):409–412.
   Google Scholar
• PILERI P, UEMATSU Y, CAMPAGNOLI S et al.: Binding of hepatitis C virus to CD81. Science (1998) 282(5390):938–941.
   PubMed Web of Science ®Google Scholar
• FARCI P, SHIMODA A, WONG D et al.: Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc. Natl. Acad. Li. USA (1996) 93(26):15394–15399.
   PubMed Web of Science ®Google Scholar
• KRAWCZYNSKI K, ALTER MJ, TANKERSLEY DL et al.: Effect of immune globulin on the prevention of experimental hepatitis C virus infection. j Infect. Dis. (1996) 173(4):822–828.
   PubMed Web of Science ®Google Scholar
• KRAWCZYNSKI K, FATTOM A, CULVER D et al.: Passive transfer of anti-HCV in chronic and acute HCV infection in chimpanzees-trials of experimental immune treatment (abstract). Hepatology (1999) 30(Suppl):423a.
   Google Scholar
• MOSMANN TR, CHERWINSKI H, BOND MW, GIEDLIN MA, COFFMAN RL: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. Inilnurrol. (1986) 136(7):2348–2357.
   Google Scholar
• KELSO A, GROVES P: A single peripheral CD8+ T cell can give rise to progeny expressing *type 1 and/or *type 2 cytokine genes and can retain its multipotentiality through many cell divisions. Proc. Nati Acad. Li. USA (1997) 94(15):8070–8075.
   PubMed Web of Science ®Google Scholar
• DIEPOLDER HM, ZACHOVAL R, HOFFMANN RIVI et al.: Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet (1995) 346(8980:1006–1007.
   PubMedGoogle Scholar
• TSAI SL, LIAW YF, CHEN MH, HUANG CY, KUO GC: Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology (1997) 25(2):449–458.
   PubMed Web of Science ®Google Scholar
• BERTOLETTI A, D'ELIOS MM, BONI C et al.: Different cytokine profiles of intrahepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology (1997) 112(1):193–199.
   Google Scholar
• NAPOLI J, BISHOP GA, MCGUINNESS PH, PAINTER DM, MCCAUGHAN GW: Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Thl-associated cytokines. Hepatology (1996) 24(4):759–765.
   PubMed Web of Science ®Google Scholar
• REISER M, MAROUSIS CG, NELSON DR et al.: Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection. Hepatol. (1997) 26(3):471–478.
   Web of Science ®Google Scholar
• PARDO M, CASTILLO I, OLIVA H et al.: A pilot study of recombinant interleukin-2 for treatment of chronic hepatitis C. Hepatology(1997) 26(5):1318–1321.
   PubMed Web of Science ®Google Scholar
• ZEIN NN, TEN RIVI, GROSS JB JR etal.: Aerosol liposomal interleukin-2 (aIL-2) combined with interferon alpha-2b/ ribavirin (IFN/R) as a novel approach in chronic hepatitis C (HCV) patients who failed previous IFN/R treatment: a preliminary report (abstract). Gastroenterology (2001) 120(5 Suppl. 1):A–77.
   Google Scholar
• LEE JH, TEUBER G, VON WAGNER M, ROTH WK, ZEUZEM S: Antiviral effect of human recombinant interleukin-12 in patients infected with hepatitis C virus. Med. Virol. (2000) 60(3):264–268.
   PubMed Web of Science ®Google Scholar
• ZEUZEM S, HOPF U, CARRENO V: A Phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C. Hepatology (1999) 29(4):1280–1287.
   PubMed Web of Science ®Google Scholar
• NELSON DR, LAUWERS GY, LAU JY, DAVIS GL: Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology (2000) 118(4):655–660.
   PubMed Web of Science ®Google Scholar
• ZEIN NN, LI H, PERSING DH: Humoral immunity in acute and chronic hepatitis C infection (letter). Gastroenterology (1999) 117(2):510.
   PubMed Web of Science ®Google Scholar
• LECHMANN M, LIANG TJ: Vaccine development for hepatitis C. Semi]. Liver Dis. (2000) 20(2):211–226.
   PubMed Web of Science ®Google Scholar
• CHIEN DY, CHOO QL, RALSTON R et al.: Persistence of HCV despite antibodies to both putative envelope glycoproteins. Lancet (1993) 342(8876):933.
   PubMed Web of Science ®Google Scholar
• WONG DK, DUDLEY DD, AFDHAL NH et al.: Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection. j Inilnurrol. (1998) 160(3):1479–1488.
   Google Scholar
• KOZIEL MJ, DUDLEY D, AFDHAL Net al.: HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J Gun. Invest. (1995) 96(5):2311–2321.
   Google Scholar
• KOZIEL MJ, WONG DK, DUDLEY D, HOUGHTON M, WALKER BD: Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons. j Infect. Dis. (1997) 176(4):859–866.
   PubMed Web of Science ®Google Scholar